e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934
February 25, 2008
Date of Report (Date of earliest event reported)
WATSON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
(State or other Jurisdiction
of Incorporation)
|
|
001-13305
(Commission File Number)
|
|
95-3872914
(IRS Employer
Identification Number) |
|
|
|
|
|
311 Bonnie Circle
Corona, California
(Address of principal
executive offices)
|
|
|
|
92880
(Zip Code) |
(951) 493-5300
(Registrants telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
|
|
|
Item 5.02 |
|
Departure of Directors and Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
2008 Cash Incentive Compensation for Chief Executive Officer.
On February 25, 2008, the Compensation Committee (the Committee) of the Board of
Directors of Watson Pharmaceuticals, Inc. (the Company) adopted a formula for determining
whether to award a cash bonus to Paul M. Bisaro, the Companys President and Chief Executive
Officer, for performance during the 2008 fiscal year. The formula is not contained in a formal
written plan. A summary of the criteria the Committee will use to determine Mr. Bisaros bonus for
fiscal year 2008 is as follows:
Mr. Bisaro will be eligible to receive a cash bonus of up to 100% of his then current salary.
Up to 70% of Mr. Bisaros award will be based upon the Companys financial performance in 2008 as
measured by Adjusted EBITDA, and up 30% of Mr. Bisaros award will be at the discretion of the
Committee, taking into account Mr. Bisaros success in:
|
(a) |
|
setting and implementing strategies to develop and grow the Companys Generic,
Brand and Distribution business segments; |
|
|
(b) |
|
implementing the Companys cost improvement initiatives, including the
integration of the Companys offshore operations; |
|
|
(c) |
|
improving the Companys quality systems and procedures; and |
|
|
(d) |
|
identifying and retaining key executives, recruiting key executives and
developing succession plans for senior leaders in the Company. |
The Committee may consider other relevant factors in its sole discretion. The Committee will
determine whether and to what extent a bonus will be paid for fiscal year 2008 after the end of
2008.
2008 Senior Executive Compensation Program.
On February 25, 2008, the Committee also adopted our 2008 Senior Executive Compensation Cash
Bonus Program (the Cash Program). The terms of the Cash Program are not contained in a
formal written plan.
Pursuant to the Cash Program and/or his or her current employment agreement, each
senior executive (other than the Chief Executive Officer) of the Company (each, an Executive
Officer) is eligible to receive an annual cash bonus targeted at a specified percentage of his
or her base salary. For 2008 these percentages range from 35% to 70% of the Executive Officers
base salary, depending on his or her position with the Company (the Target Bonus).
The bonus paid to an Executive Officer can range from 0% to 150% of the Executive Officers
Target Bonus, depending to varying degrees on (i) the Companys financial performance in 2008 as
measured by Adjusted EBITDA, (ii) the contribution of the Executive Officers business segment to
the Companys performance (where applicable) and (iii) the performance of the Executive Officer and
his or her department during 2008 as determined by our CEO. The application of the above factors
in determining annual cash bonus awards varies by the position and segment of the Executive Officer
with the following ranges:
|
|
|
For our Generic and Brand Presidents, forty percent (40%) of the Executive Officers
award is based upon the Companys performance as measured by Adjusted EBITDA, forty
percent |
|
|
|
(40%) of the Executive Officers award is based on the Adjusted Contribution of the
Presidents business segment to the Companys financial results and twenty percent (20%) of the
Executive Officers award is based on the individual
performance of the Executive Officer. |
|
|
|
|
For our other Executive Officers in our Brand and Generic Segments forty percent (40%)
of the Executive Officers award is based upon the Companys performance as measured by
Adjusted EBITDA, thirty percent (30%) of the Executive Officers award is based on the
Adjusted Contribution of the Executive Officers business segment to the Companys
financial results and thirty percent (30%) of the Executive Officers award is based on the
individual performance of the Executive Officer and the performance of his or her
department. |
|
|
|
|
For the head of our Distribution Segment, twenty percent (20%) of the Executive
Officers award is based upon the Companys performance as measured by Adjusted EBITDA,
sixty percent (60%) of the Executive Officers award is based on the Anda Adjusted
Contribution of the Executive Officers business segment to the Companys financial
results, and twenty percent (20%) of the Executive Officers award is based on the
Executive Officers individual performance. |
|
|
|
|
For Executive Officers classified as Shared Services (including our Chief Financial
Officer and our General Counsel) sixty percent (60%) of the Executive Officers award is
based upon the Companys performance as measured by Adjusted EBITDA and forty percent (40%)
of the Executive Officers award is based on the individual performance of the Executive
Officer and the performance of his or her department. |
The total amount of cash bonus payable to an Executive Officer may be further adjusted by up
to twenty five percent (25%) at the discretion of the Committee. The Committee will determine
whether and to what extent cash bonuses will be paid for fiscal year 2008 after the end of 2008.
For the purposes of determining the bonus amounts for Mr. Bisaro and the Executive Officers:
Adjusted EBITDA means the Companys earnings before interest, taxes, depreciation and
amortization, adjusted for share-based compensation, acquisition or licensing related charges,
restructuring charges, litigation charges, charges associated with the Companys global supply
chain initiative, non-cash charges, gains or losses on debt repurchase, gains or losses on sales of
operating assets or securities and such other special items as determined at the discretion of the
Companys Board of Directors.
Adjusted Contribution means a business segments contribution (as reported in the
Companys filings with the U.S. Securities and Exchange Commission) adjusted for any reconciling item of the relevant segment that has been
excluded in determining Adjusted EBITDA; and
Anda Adjusted Contribution means the distribution segments contribution (as reported
in the Companys filings with the U.S. Securities and Exchange Commission) plus 25% of manufactured sales (as defined by the Company) less the distribution segments
general and administrative costs. This amount is adjusted for any reconciling item that has been
excluded in determining the Companys Adjusted EBITDA.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Dated: February 29, 2008 |
WATSON PHARMACEUTICALS, INC.
|
|
|
By: |
/s/ David A. Buchen
|
|
|
|
David A. Buchen |
|
|
|
Senior Vice President, General Counsel and
Secretary |
|
|